Myomo combines rapid top-line growth and improving margins with a solid liquidity position and a distinctive, clinically focused technology platform. Its strong patent portfolio, early leadership in a focused niche, growing reimbursement coverage, and expanding patient pipeline all support the view that it has carved out a real opportunity within neuro-robotic rehabilitation.

The main concerns center on ongoing losses, consistently negative free cash flow, and a heavy reliance on external capital to fund operations and growth. Accumulated deficits, rising lease-related debt, competition from larger and better-capitalized players, and uncertainty around regulatory approvals and reimbursement policies add meaningful execution and financial risk.

Taken together, the data point to a company moving in the right direction but still in an early, high-risk phase. If Myomo can sustain strong revenue growth, continue to expand reimbursement, and convert its R&D and international initiatives into profitable scale, its financial profile could improve markedly over time; however, that path is likely to be uneven and heavily dependent on both operational execution and the availability of supportive capital markets.